Ayahuasca

Traditional and indigenous use

Ayahuasca has been used ceremonially for centuries across dozens of indigenous groups in northwestern Amazonia — in present-day Brazil, Peru, Colombia, Ecuador, Bolivia, and Venezuela.^[3][6] Ceremonial uses include healing, divination, initiation, and spiritual purification. The brew carries different names across cultures: ayahuasca (Quechua), natem (Shuar, Ecuador), yagé (Tukano, Colombia), and hoasca or vegetal in Brazilian syncretic churches. Ethnographic documentation extends at least to the 17th century.^[11] Emetic and purgative effects are culturally integral — understood as cleansing rather than a side effect.^[6]

Western discovery and research

The English botanist Richard Spruce formally described the vine during his 1849–1864 Amazonian expedition; the accepted binomial Banisteriopsis caapi was formalized in 1931.^[12] In 1984, McKenna, Towers, and Abbott established that the beta-carboline alkaloids act as MAO-A inhibitors — explaining why DMT is active when consumed orally.^[1] The first European double-blind controlled clinical studies ran from 1999 to 2003,^[13][2] and a first fMRI study confirmed default mode network suppression in 2015.^[14]

Modern research and regulation

Brazil first formally regulated ayahuasca in 1987, authorizing religious and ceremonial use — the world's first national regulatory framework for the preparation. The U.S. Supreme Court upheld Religious Freedom Restoration Act protections for the União do Vegetal in 2006; Peru declared ceremonial use a national cultural heritage in 2008. The first randomized placebo-controlled trial in treatment-resistant depression, published in 2018, reported a 64% response rate versus 27% for placebo,^[5] and 26 registered interventional trials are active as of 2026.^[4] Meta-analytic data report a large pooled effect size in mood disorders,^[15] though broader pooled analysis yields a more conservative estimate at very low evidence certainty.^[16]

Banisteriopsis caapi (Spruce ex Griseb.) C.V.Morton belongs to the family Malpighiaceae. It is a large woody climbing vine native to the tropical lowland forests of the Amazon basin and adjacent South American regions. Psychotria viridis Ruiz & Pav. (Rubiaceae), the most common DMT-containing admixture plant, is an understory shrub native to the same Amazonian forests.

Both species are cultivated in tropical gardens throughout South America and increasingly worldwide. Wild populations remain abundant in intact Amazonian forest. The vine is harvested by cutting mature stems into sections; P. viridis leaves are picked fresh for brewing.

B. caapi is identified by its smooth greyish-brown bark that peels in longitudinal strips, opposite leaves, and a distinctive pattern of concentric rings in cross-section. P. viridis has glossy dark green elliptical leaves with prominent venation and small red berrylike fruits. Diplopterys cabrerana — known as chagropanga or chaliponga — serves as the DMT source in some Colombian and Ecuadorian traditions in place of P. viridis. Additional botanicals including tobacco (Nicotiana rustica) and Brugmansia species may be added to specific ceremonial preparations, significantly altering the pharmacological and safety profile.

Ayahuasca's effects arise from two alkaloid classes working together. The vine B. caapi supplies beta-carboline alkaloids — primarily harmine, harmaline, and tetrahydroharmine — that block MAO-A, the enzyme that would otherwise break down DMT in the gut before it reaches the brain. Without that block, orally consumed DMT is roughly 97% metabolized before reaching the brain and produces no psychoactive effect.^[17]

Harmine is the most abundant beta-carboline and the primary MAO-A inhibitor;^[1] it also inhibits the DAT.^[18] Harmaline acts as a secondary MAO-A inhibitor with greater preclinical toxicity concerns than harmine.^[19] Tetrahydroharmine inhibits serotonin reuptake — a separate mechanism that may contribute a mild anxiolytic component.^[20][21] The admixture plant provides DMT, which activates serotonin receptors in the cortex and drives the psychedelic state;^[2] DMT also engages several other receptor systems.^{[3][22][21][11]}

Alkaloid concentrations vary dramatically between preparations. Analyzed brews show DMT concentrations ranging from 0.05 to 14.2 mg/mL^[7] — a 280-fold spread. Vine-to-leaf ratios, brewing duration, water volume, and plant cultivar all contribute. A "standard dose" cannot be established without laboratory testing.

Where it acts

Once MAO-A is inhibited, DMT enters the brain and activates serotonin receptors on neurons in the cortex. Neuroimaging shows that this suppresses the default mode network — the brain circuit associated with self-referential thought and rumination — particularly in regions linked to self-awareness and planning.^[14][23] Frontal and emotional brain regions become more active at the same time. This disruption of top-down control, combined with heightened sensory and emotional flow, underlies the ego dissolution and introspective intensity of the experience.citation needed

What it changes

DMT's action at sigma-1 receptors contributes anti-inflammatory and neuroprotective effects independent of its psychedelic action.^[24] After the experience, proteins involved in neuronal growth and rewiring are elevated, and structural brain changes may persist well beyond the acute state.^[25] EEG recordings show reduced alpha-wave activity in visual brain regions during the experience, correlating with the intensity of visual imagery.^[2]

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

Moderate cardiovascular effects occur: diastolic blood pressure rises approximately 9 mmHg at 0.85 mg DMT/kg, accompanied by elevated heart rate, prolactin, and cortisol.^[13][28]

Animal studies show developmental toxicity: at twice the human equivalent dose during gestation, neuronal loss occurs in the hippocampus; at four to eight times the human equivalent dose, maternal mortality reached 44–52%.^[10] Pregnancy is an absolute contraindication.

Contaminant and adulterant risk: No standardized quality control exists — alkaloid content varies from 0.05 to 14.2 mg/mL between analyzed batches.^[7] Some ceremonial preparations include undisclosed Brugmansia or Datura containing tropane alkaloids (scopolamine, atropine), creating anticholinergic toxicity risk on top of the serotonergic effects. Ehrlich reagent confirms the presence of indole alkaloids but does not quantify concentration or detect non-indole adulterants.

SSRIs and SNRIs raise this risk through two mechanisms: serotonergic accumulation, and elevated DMT and harmine blood levels, because fluoxetine and paroxetine also block CYP2D6, the enzyme that clears these alkaloids.^[9] Minimum washout: 2 weeks for most SSRIs and SNRIs; 5 weeks for fluoxetine.

• Irreversible MAOIs (phenelzine, tranylcypromine): additive MAO-A inhibition; high serotonin syndrome risk.
• Tramadol: combined serotonergic potentiation and CYP2D6 interaction; seizure threshold reduction.
• Lithium: seizure risk noted in harm reduction literature.safety citation needed
• Stimulants (amphetamines, cocaine): additive sympathomimetic and serotonergic effects; compounded cardiovascular risk.
• Antipsychotics: may blunt psychedelic effects at 5-HT₂A; QTc prolongation risk with concurrent use.

Contraindications

DMT is Schedule I under the 1971 United Nations Convention on Psychotropic Substances. However, the UN treaties do not schedule the plants themselves — Banisteriopsis caapi and Psychotria viridis are not listed in the 1961, 1971, or 1988 drug control conventions.^[33] This creates divergent national approaches: some countries treat ayahuasca brews as illegal DMT preparations, while others carve out explicit protections for religious or traditional ceremonial use. In the United States, ayahuasca is federally illegal under Schedule I, though two religious organizations — União do Vegetal (upheld by Supreme Court in 2006) and Santo Daime — hold court-protected exemptions under the Religious Freedom Restoration Act. Brazil authorized religious and ceremonial use in 1987; Peru recognizes traditional ceremonial use as national cultural heritage. The United Kingdom, the Netherlands, and Germany prohibit it due to DMT content, with no religious exemptions. Canada classifies DMT as Schedule III. Standard urine drug screens do not detect DMT or beta-carboline alkaloids — detection requires specialized laboratory analysis, and in one study of religious users, DMT and beta-carbolines were detectable in saliva and serum for approximately 24 hours post-ingestion.^[34]